Darolutamide (Nubeqa®)
Prostate Cancer (Various stages)
Marketed / Phase 3Marketed, ongoing label expansion trials
Key Facts
Indication
Prostate Cancer (Various stages)
Phase
Marketed / Phase 3
Status
Marketed, ongoing label expansion trials
Company
About Orion Corporation
Orion Corporation is a century-old, publicly traded Finnish pharmaceutical leader with a dual-pillar strategy: developing proprietary drugs in CNS, oncology, and respiratory diseases, and operating a leading contract manufacturing (Fermion CDMO) business. Its major achievement is the global success of Nubeqa® (darolutamide) for prostate cancer, developed with Bayer, which anchors its growing oncology franchise. The company's vertically integrated operations, substantial pipeline, and resilient revenue model position it for sustainable growth in specialty pharma and the CDMO sector.
View full company profile